Literature DB >> 20412696

Serum levels of BAFF for assessing the disease activity of Takayasu arteritis.

Yuichiro Nishino1, Mami Tamai, Atsushi Kawakami, Tomohiro Koga, Junya Makiyama, Yumi Maeda, Yuka Jiuchi, Taichiro Miyashita, Yasumori Izumi, Katsumi Eguchi, Kiyoshi Migita.   

Abstract

OBJECTIVES: Takayasu arteritis (TA) is a chronic vasculitis that affects large elastic arteries. Monitoring of disease activity is crucial because the disease may progress despite treatment with glucocorticoids. Elevated levels of B cell activating factor belonging to TNF family (BAFF) have been observed in patients with autoimmune diseases. In this study, we investigated whether dysregulation of BAFF occurs in TA.
METHODS: Serum levels of BAFF were measured in sera from 9 patients with TA including 6 patients with follow up after induction therapy.
RESULTS: Circulating BAFF levels in TA patients were higher than in those in healthy subjects. The high levels of BAFF in active TA patients were decreased when the patients entered remission.
CONCLUSIONS: To our knowledge, this is the first study to show elevated levels of BAFF in active TA patients. These findings suggest that this cytokine contributes to vasculitis in TA and raise the possibility that monitoring of serum BAFF might aid clinicians in making adequate treatment adjustments in TA patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20412696

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  7 in total

Review 1.  Assessment of disease activity and progression in Takayasu's arteritis.

Authors:  Haner Direskeneli; Sibel Z Aydin; Peter A Merkel
Journal:  Clin Exp Rheumatol       Date:  2011-05-11       Impact factor: 4.473

2.  Serum BAFF and APRIL levels in Indian patients with Takayasu arteritis.

Authors:  Abhishek Zanwar; Avinash Jain; Latika Gupta; Smirti Chaurasia; Sandeep Kumar; Durga Prasanna Misra; Ramnath Misra
Journal:  Clin Rheumatol       Date:  2018-07-11       Impact factor: 2.980

3.  High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statins.

Authors:  Alexandre W S de Souza; Kornelis S M van der Geest; Elisabeth Brouwer; Frederico A G Pinheiro; Ana Cecília Diniz Oliveira; Emília Inoue Sato; Luis Eduardo C Andrade; Marc Bijl; Johanna Westra; Cees G M Kallenberg
Journal:  Arthritis Res Ther       Date:  2015-06-12       Impact factor: 5.156

Review 4.  Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.

Authors:  Aleksander Lenert; Petar Lenert
Journal:  Drug Des Devel Ther       Date:  2015-01-07       Impact factor: 4.162

Review 5.  Blood Biomarkers for Monitoring and Prognosis of Large Vessel Vasculitides.

Authors:  Enrico Tombetti; Elvis Hysa; Justin C Mason; Marco A Cimmino; Dario Camellino
Journal:  Curr Rheumatol Rep       Date:  2021-02-10       Impact factor: 4.592

6.  Decreased Absolute Number of Circulating Regulatory T Cells in Patients With Takayasu's Arteritis.

Authors:  Wen Jia; Zi-Li Fu; Xia Wang; Jing Luo; Cheng-Lan Yan; Jian-Ping Cao; Jian-Fang Xie; Guang-Ying Liu; Chong Gao; Xiao-Feng Li
Journal:  Front Immunol       Date:  2021-12-23       Impact factor: 7.561

7.  Biomarker Changes and Molecular Signatures Associated with Takayasu Arteritis Following Treatment with Glucocorticoids and Tofacitinib.

Authors:  Xiaojuan Dai; Jinghua Wang; Xiao Zhang; Li Wang; Sifan Wu; Huiyong Chen; Ying Sun; Lili Ma; Lingying Ma; Xiufang Kong; Lindi Jiang
Journal:  J Inflamm Res       Date:  2022-08-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.